Literature DB >> 9200777

Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies.

A M Alak1.   

Abstract

Tacrolimus (FK506, Prograf) is a macrolide immunosuppressant used for the prevention of organ rejection after transplantation. Tacrolimus demonstrates considerable interindividual variation in its pharmacokinetic profile. This has caused difficulty in defining the optimum regimen and has highlighted the need for therapeutic drug monitoring. Several assay methods for the measurements of tacrolimus in biological specimens have been developed. These assay methods were used for therapeutic drug monitoring and/or pharmacokinetic studies. Two commercially available immunoassays, based on the same monoclonal antibody to tacrolimus, have been used for therapeutic drug monitoring of tacrolimus in whole blood. For pharmacokinetic studies, the assay methods were used to measure tacrolimus and its metabolites in very low concentrations in selected biological matrixes to determine the metabolic and pharmacokinetic profiles of this drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200777     DOI: 10.1097/00007691-199706000-00016

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients.

Authors:  Yan-xia Lu; Qing-hong Su; Ke-hua Wu; Yu-peng Ren; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

Review 2.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice.

Authors:  K Yokogawa; M Takahashi; I Tamai; H Konishi; M Nomura; S Moritani; K Miyamoto; A Tsuji
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

4.  Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation.

Authors:  V Guy-Viterbo; A Scohy; R K Verbeeck; R Reding; P Wallemacq; Flora Tshinanu Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

5.  Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation.

Authors:  Flora T Musuamba; Michel Mourad; Vincent Haufroid; Martine De Meyer; Arnaud Capron; Isabelle K Delattre; Roger K Verbeeck; Pierre Wallemacq
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

6.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 7.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.